Predictive IHC Markers in Breast Cancer 2020: What Have We Learned?
Recorded On: 10/15/2020
This workshop will review the current state of immunohistochemical testing for estrogen receptor protein, progesterone receptor protein, and HER2 protein overexpression in breast cancer. Invasive, metastatic, and in situ cancer will be covered. The importance of pre-analytics and technical issues in IHC testing will be addressed. Proficiency testing and results from Oncotype DX™ testing will be used to discuss standardization and test validation.
CEUs: This histology course is worth 1 continuing education credit. Course is available for 365 days from date of purchase.
Richard Cartun, MS, PhD
Director, Histology/Morphologic Proteomics
I currently serve as the Director of Histology, Immunopathology, and the Martin M. Berman, MD Morphologic Proteomics Laboratory at Hartford Hospital, a large tertiary care hospital in Hartford, CT. I have been doing immunohistochemical testing for more than 40 years now and, as a result, have extensive knowledge in the technical aspects and interpretation of this valuable laboratory test.